|
|
 Cialis
Bibliography
Below are some articles relating to Cialis (Tadalafil)
for further reading.
1: Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G.
Time course of the interaction between tadalafil and nitrates.
J Am Coll Cardiol. 2003 Nov 19;42(10):1855-60.
2: Keating GM, Scott LJ.
Vardenafil : A Review of its Use in Erectile Dysfunction.
Drugs. 2003;63(23):2673-2703.
3: Scheen AJ.
[In Process Citation]
Rev Med Liege. 2003 Sep;58(9):576-9. French.
4: Bella AJ, Brock GB.
Tadalafil in the treatment of erectile dysfunction.
Curr Urol Rep. 2003 Dec;4(6):472-8.
5: Francis SH, Corbin JD.
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.
Curr Urol Rep. 2003 Dec;4(6):457-65.
6: Carson III CC.
Tadalafil for the treatment of erectile dysfunction.
Curr Urol Rep. 2003 Dec;4(6):455-6. No abstract available.
7: Kloner RA, Brindis RG, Cheitlin MD, Kuritzky L, Miller TA, Padma-Nathan H,
Rosen RC.
Roundtable discussion: tadalafil study group.
Am J Cardiol. 2003 Nov 6;92(9A):58M-65M. No abstract available.
8: Kloner RA, Mitchell M, Emmick JT.
Cardiovascular effects of tadalafil in patients on common antihypertensive
therapies.
Am J Cardiol. 2003 Nov 6;92(9A):47M-57M. Review.
9: Kloner RA, Mitchell M, Emmick JT.
Cardiovascular effects of tadalafil.
Am J Cardiol. 2003 Nov 6;92(9A):37M-46M. Review.
10: Padma-Nathan H.
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor,
in treatment of erectile dysfunction.
Am J Cardiol. 2003 Nov 6;92(9A):19M-25M. Review.
11: Rosen RC, Kostis JB.
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Am J Cardiol. 2003 Nov 6;92(9A):9M-18M. Review.
12: Seftel A.
Effects of tadalafil on erectile dysfunction in men with diabetes.
J Urol. 2003 Aug;170(2 Pt 1):679-80. No abstract available.
13: Meuleman EJ.
Review of tadalafil in the treatment of erectile dysfunction.
Expert Opin Pharmacother. 2003 Nov;4(11):2049-56.
14: Minhas S, Kalsi JS, Ralph DJ.
Cialis (tadalafil): a new treatment for erectile dysfunction.
Hosp Med. 2003 Oct;64(10):589-92. Review.
15: Schultheiss D, Stief CG.
[In Process Citation]
Urologe A. 2003 Oct;42(10):1322-9. German.
16: Kim NN.
Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation
survey.
Int J Impot Res. 2003 Oct;15 Suppl 5:S13-9. Review.
17: Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Linget
JM, Kirilovsky J, Hyafil F, Labaudiniere R.
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2:
2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
analogues.
J Med Chem. 2003 Oct 9;46(21):4533-42.
18: Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H,
Kirilovsky J, Hyafil F, Labaudiniere R.
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1:
5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione
analogues.
J Med Chem. 2003 Oct 9;46(21):4525-32.
19: Porst H; Urological Practice, Hamburg, Germany.
Tadalafil: a viewpoint by hartmut porst.
Drugs. 2003;63(20):2213-4. No abstract available.
20: McMahon C; Australian Centre for Sexual Health, St. Luke's Hospital,
Sydney, New South Wales, Australia.
Tadalafil: A Viewpoint by Chris G. McMahon.
Drugs. 2003;63(20):2213-4. No abstract available.
21: Curran M, Keating G.
Tadalafil.
Drugs. 2003;63(20):2203-12; discussion 2213-4.
22: Sung BJ, Yeon Hwang K, Ho Jeon Y, Lee JI, Heo YS, Hwan Kim J, Moon J, Min
Yoon J, Hyun YL, Kim E, Jin Eum S, Park SY, Lee JO, Gyu Lee T, Ro S, Myung Cho
J.
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug
molecules.
Nature. 2003 Sep 4;425(6953):98-102.
23: Shabsigh R.
Hypogonadism and erectile dysfunction: the role for testosterone therapy.
Int J Impot Res. 2003 Aug;15 Suppl 4:S9-13.
24: Kuthe A.
Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Curr Opin Urol. 2003 Sep;13(5):405-10.
25: Hellstrom WJ, Overstreet JW, Yu A, Saikali K, Shen W, Beasley CM Jr,
Watkins VS.
Tadalafil has no detrimental effect on human spermatogenesis or reproductive
hormones.
J Urol. 2003 Sep;170(3):887-91.
26: Roumeguere T, Sternon J, Schulman CC.
[Erectile dysfunction and phosphodiesterase type 5 inhibitors]
Rev Med Brux. 2003 Jun;24(3):169-75. Review. French.
27: Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R.
Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36
hours after dosing: a randomized controlled trial.
Urology. 2003 Jul;62(1):121-5; discussion 125-6.
28: Rosen RC, McKenna KE.
PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical
outcomes.
Annu Rev Sex Res. 2002;13:36-88. Review.
29: Sperling H, Lummen G, Schneider T, Rubben H.
[New treatment options for erectile dysfunction. Pharmacologic and
nonpharmacologic options]
Herz. 2003 Jun;28(4):314-24. German.
30: Bayes M, Rabasseda X, Prous JR.
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. Review.
31: Junemann KP.
[How effective are PDE-5 inhibitors?]
Urologe A. 2003 Apr;42(4):553-8. Epub 2003 Mar 25. German.
32: Pomerol JM, Rabasseda X.
Tadalafil, a further innovation in the treatment of sexual dysfunction.
Drugs Today (Barc). 2003 Feb;39(2):103-13. Review.
33: Holmes S.
Tadalafil: a new treatment for erectile dysfunction.
BJU Int. 2003 Apr;91(6):466-8. No abstract available.
34: Brock GB.
Tadalafil: a new agent for erectile dysfunction.
Can J Urol. 2003 Feb;10 Suppl 1:17-22. Review.
35: Carrier S.
Pharmacology of phosphodiesterase 5 inhibitors.
Can J Urol. 2003 Feb;10 Suppl 1:12-6. Review.
36: Rotella DP.
Tadalafil Lilly ICOS.
Curr Opin Investig Drugs. 2003 Jan;4(1):60-5. Review.
37: Bayes M, Rabasseda X, Prous JR.
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.
38: Bayes M, Rabasseda X, Prous JR.
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):615-43.
39: Montorsi F, Salonia A, Deho' F, Cestari A, Guazzoni G, Rigatti P, Stief C.
Pharmacological management of erectile dysfunction.
BJU Int. 2003 Mar;91(5):446-54. Review.
40: Rodriquez Vela L, Gonzalvo Ibarra A, Pascual Regueiro D, Rioja Sanz LA.
[Erectile dysfunction]
Actas Urol Esp. 2002 Oct;26(9):667-90. Review. Spanish.
41: Bayes M, Rabasseda X, Prous JR.
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):525-51.
42: Vickers MA, Satyanarayana R.
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
in patients with diabetes mellitus.
Int J Impot Res. 2002 Dec;14(6):466-71.
43: Saenz de Tejada I, Anglin G, Knight JR, Emmick JT.
Effects of tadalafil on erectile dysfunction in men with diabetes.
Diabetes Care. 2002 Dec;25(12):2159-64.
44: Kuan J, Brock G.
Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment
of erectile dysfunction.
Expert Opin Investig Drugs. 2002 Nov;11(11):1605-13. Review.
45: Gresser U, Gleiter CH.
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5
inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Eur J Med Res. 2002 Oct 29;7(10):435-46. Review.
46: Bayes M, Rabasseda X, Prous JR.
Gateways to Clinical Trials.
Methods Find Exp Clin Pharmacol. 2002 Sep;24(7):431-55. Review.
47: Vitezic D, Pelcic JM.
Erectile dysfunction: oral pharmacotherapy options.
Int J Clin Pharmacol Ther. 2002 Sep;40(9):393-403. Review.
48: Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G,
Whitaker S.
Efficacy and safety of tadalafil for the treatment of erectile dysfunction:
results of integrated analyses.
J Urol. 2002 Oct;168(4 Pt 1):1332-6.
49: Corbin JD, Francis SH.
Pharmacology of phosphodiesterase-5 inhibitors.
Int J Clin Pract. 2002 Jul-Aug;56(6):453-9. Review.
50: Eardley I, Cartledge J.
Tadalafil (Cialis) for men with erectile dysfunction.
Int J Clin Pract. 2002 May;56(4):300-4.
51: Porst H.
IC351 (tadalafil, Cialis): update on clinical experience.
Int J Impot Res. 2002 Feb;14 Suppl 1:S57-64. Review.
|
